Niu Tirī: Hei whakautu i tētahi tono a Fresenius Medical Care, kua tūtohu te Komiti Tohunga Motuhake (SEC) o te Whakahaere Mana Paerewa Rongoā Matua (CDSCO) kia tukuna e te kamupene te take mō te whakaaetanga me ngā raraunga whakamātautau haumanu wāhanga tuatoru o te konupūmā hauota dihydrate me ngā raraunga tirotiro hokohoko muri mai i ngā whenua kua whakaaetia hei whakaaroaro anō.
I mua, i tukuna e te kamupene he tono hei hanga me te hokohoko i te otinga konupūmā hauota dihydrate i te kukū o te 100 mmol/L, e whakamahia ana mō te "whakaora whakakapinga konupūmā i roto i te whakaora whakakapinga whatukuhu tonu (CRRT), te dialysis iti-whai hua tonu (ia rā) (CLED) me te whakawhiti plasma rongoā (TPE) me te citrate anticoagulation. He pai te hua mō ngā pakeke me ngā tamariki" me te kī i ngā take mō te tango i ngā whakamātautau haumanu wāhanga III me te wāhanga IV.
I kite te komiti kua whakaaetia te hua i ngā whenua Pākehā pērā i a Potukara, te United Kingdom, Brazil, Switzerland, France me Denmark.
Ko te matū konupūmā hauota dihydrate ko CaCl2 2H2O, he konupūmā hauota kei roto e rua ngā ngota wai mō ia waeine konupūmā hauota. He matū tioata mā, he ngāwari te wairewa ki te wai, ā, he higroscopic, arā, ka taea te mimiti i te makuku mai i te hau.
He matū te konupūmā hauota dihydrate ka taea te whakamahi hei pūnaha whakarewa hei whakarewa i te chitin ina whakarewaina ki te methanol. He mea nui tana mahi ki te wawahi i te hanganga tioata o te chitin, ā, he whānuitia ana whakamahinga i roto i te ao matū.
I te hui a te SEC Nephrology i tū i te 20 o Mei, 2025, i arotakehia e te rōpū te tono kia whakaaetia te hanga me te hokohoko i te otinga whaowhia konupūmā hauota dihydrate 100 mmol/L hei whakamahi i roto i te "whakaora whakakapinga konupūmā i roto i te whakaora whakakapinga whatukuhu tonu (CRRT), te dialysis iti-whai hua tonu (ia rā) (SLEDD), me te whakawhiti plasma rongoā (TPE) me te citrate anticoagulation. E tohua ana te hua mō ngā pakeke me ngā tamariki" ā, i whakaratohia he whakamārama mō ngā whakawāteatanga mai i ngā whakamātautau haumanu wāhanga III me te IV.
Whai muri i te kōrero taipitopito, i tūtohu te komiti kia tukuna te pūtake mō te whakaaetanga, me ngā raraunga whakamātautau haumanu wāhanga tuatoru me ngā raraunga tirotiro i muri i te hokohoko mai i ngā whenua kua whakaae ki te rongoā, ki te komiti hei whakaaroaro anō.
Pānuihia hoki: Kua Whakaaetia e te Rōpū CDSCO te Tapanga Whakahou mō te Myozyme a Sanofi, me te Tono Arotake Ture
He tauira paetahi a Tākuta Divya Kolin i te tohu PharmD, he nui ōna wheako haumanu me te hōhipera, ā, he tino pai hoki ōna pūkenga tātaritanga me te rongoā. I mahi anō hoki ia hei kaiwhakaora rongoā mate pukupuku i te tari mate pukupuku i te Mysore Medical College and Research Institute. Kei te whai tonu ia i tana mahi i roto i te rangahau haumanu me te whakahaere raraunga haumanu. Mai i te marama o Hānuere 2022, kua mahi ia ki Medical Dialogue.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
I kitea i roto i te rangahau a ABYSS ko te whakamutu i ngā beta-blockers i muri i te myocardial infarction i hua ake ai te pikinga o te toto toto, te tere o te ngakau, me ngā pānga kino o te pūnaha cardiovascular: …